Lipocine's TLANDO Oral TRT Solution Seeks FDA Approval in Canada, Analysts Expect 132% Upside

Lipocine (LPCN) has filed a New Drug Submission (NDS) for TLANDO in Canada, potentially opening the Canadian market to the oral testosterone replacement therapy. The company expects this innovation to enhance its market presence. Two analysts have set a one-year price target for LPCN at $7.38, with an upside of 132.65% from the current price. The average brokerage recommendation is 2.0, indicating an "Outperform" status.